Gilead Sciences GILD Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $29.74B+3.5% | $29.44B+2.4% | $29.09B+2.8% | $28.86B+3.8% | $28.74B+4.7% | ||
| $6.14B-1.6% | $6.23B-0.3% | $6.19B-8.4% | $6.2B-8.2% | $6.24B-6.2% | ||
| $23.6B+4.9% | $23.21B+3.1% | $22.9B+6.3% | $22.67B+7.7% | $22.5B+8.1% | ||
| 79.4%+1.1pp | 78.8%+0.6pp | 78.7%+2.6pp | 78.5%+2.8pp | 78.3%+2.5pp | ||
| $5.97B-0.1% | $5.77B-5.2% | $5.89B+1.6% | $5.96B+5.1% | $5.98B-2.8% | ||
| $19.37B-5.6% | $19.42B-28.3% | $18.6B-32.3% | $20.81B-17.6% | $20.51B-20.7% | ||
| $10.37B+26.2% | $10.02B+503% | $10.49B+1,176% | $8.05B+215% | $8.22B+421% | ||
| 34.9%+6.3pp | 34%+28.3pp | 36.1%+33.2pp | 27.9%+18.7pp | 28.6%+22.9pp | ||
| $1.01B+2.1% | $1.03B+4.8% | $1.02B+3.9% | $1B+2.7% | $984M+1.7% | ||
| $1.36B— | $798M— | —— | —— | —— | ||
| $10.73B+57.2% | $9.8B+1,320% | $9.89B+5,517% | $7.2B+368% | $6.83B+536% | ||
| $1.62B+87.9% | $1.39B+559% | $1.78B+2,719% | $890M+75.9% | $860M+39.4% | ||
| $9.22B+54.5% | $8.51B+1,673% | $8.11B+6,337% | $6.31B+499% | $5.97B+1,132% | ||
| 31%+10.2pp | 28.9%+27.2pp | 27.9%+27.4pp | 21.9%+18.1pp | 20.8%+19.0pp | ||
| $7.34+54.5% | $6.77+1,730% | $6.45+7,962% | $5.02+520% | $4.75+1,257% | ||
| $10.74B+24.8% | $10.39B+409% | $10.87B+806% | $8.43B+139% | $8.61B+175% | ||
| 36.1%+6.2pp | 35.3%+28.2pp | 37.4%+33.1pp | 29.2%+16.5pp | 29.9%+18.6pp | ||
| $10.37B+26.2% | $10.02B+503% | $10.49B+1,176% | $8.05B+215% | $8.22B+421% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Gilead Sciences's revenue?
- Gilead Sciences (GILD) generated $29.7B in revenue over the trailing twelve months, up 3.5% year over year.
- Is Gilead Sciences profitable?
- Gilead Sciences reported $9.2B in net income over the trailing twelve months, a 31.0% net margin.
- What are Gilead Sciences's profit margins?
- Gross margin is 79.4% and operating margin is 34.9%, with a 31.0% net margin.
- What is Gilead Sciences's earnings per share?
- Gilead Sciences's diluted EPS over the trailing twelve months is $7.34.
- Where does Gilead Sciences's income statement data come from?
- Every line is extracted from Gilead Sciences's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
